Used primarily as a prodrug in pharmaceutical applications, this compound is designed to enhance the bioavailability of active benzimidazole-based therapeutics. Its structure allows for controlled release of the parent drug through enzymatic hydrolysis in vivo, making it valuable in treatments requiring sustained drug delivery. It is particularly explored in cardiovascular and metabolic therapies due to its targeted activation and improved pharmacokinetic profile. The ethyltetrazole moiety contributes to receptor binding affinity, while the ester linkage enables metabolic stability and gradual conversion to the active form. This makes it suitable for oral formulations where consistent plasma levels are critical.